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 230 
Highlights: 231 
 TKIs suppress the production of pro-inflammatory cytokines in vitro, including IL17 232 
 TKIs reduce the frequency of total Tregs in vitro but preserve naïve subsets 233 
 B and NK cells are impaired by TKIs in vitro, whereas T cells are preserved 234 
 Comparable results were obtained in patients treated with Nilotinib for cGVHD 235 
 236 
Abstract  237 
Pathogenesis of chronic Graft Versus Host Disease (cGVHD) is incompletely defined, involving 238 
donor-derived CD4 and CD8-positive T lymphocytes, as well as B cells. Standard treatment is 239 
lacking for steroid dependent/refractory cases; potential usefulness of tyrosine kinase inhibitors 240 
(TKIs) has been suggested, based on their potent anti-fibrotic effect. However, TKI seems to have 241 
pleiotropic activity. We sought to evaluate the in vitro and in vivo impact of different TKIs on 242 
lymphocyte phenotype and function. Peripheral blood mononuclear cells (PBMC) from healthy 243 
donors were cultured in presence of increasing concentrations of Nilotinib, Imatinib, Dasatinib and 244 
Ponatinib; in parallel 44 PBMC samples from 15 patients with steroid-dependent/refractory 245 
cGVHD treated with Nilotinib in the setting of a phase 1-2 trial were analyzed at baseline, after 90 246 
and after 180 days of therapy. Flow cytometry was performed after labelling lymphocytes with a 247 
panel of monoclonal antibodies (CD3, CD4, CD16, CD56, CD25, CD19, CD45RA, FoxP3, CD127 and 248 
7AAD). Cytokine production was assessed in supernatants of purified CD3+ T cells and in plasma 249 
samples from Nilotinib-treated patients. Main T lymphocytes subpopulations were not 250 
significantly affected by therapeutic concentrations of TKIs in vitro, whereas pro-inflammatory 251 
cytokine (in particular IL2, IFNγ, TNFα and IL10) and IL17 production showed a sharp decline. 252 
Frequency of T regulatory, B and NK cells decreased progressively in presence of therapeutic 253 
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concentrations of all the TKIs tested in vitro, except for Nilotinib that showed little effect on these 254 
subsets; of note, naïve T regulatory cell subset accumulated following exposure to TKIs. Results 255 
obtained in vivo on Nilotinib-treated patients were largely comparable, both on lymphocyte subset 256 
kinetics and on cytokine production by CD3-positive cells. This study underlines the anti-257 
inflammatory and immunomodulatory effects of TKIs, and support their potential usefulness as 258 
treatment for patients with steroid dependent/refractory cGVHD. In addition, both in vitro and in 259 
vivo data point out that, compared to other TKIs, Nilotinib could better preserve the integrity of 260 
some important regulatory subsets, such as T regulatory and NK cells. 261 
 262 
Introduction 263 
Chronic Graft Versus Host Disease (cGVHD) is a major complication of allogeneic stem cell 264 
transplantation (allo-SCT) and is characterized by multi-organ involvement resembling 265 
autoimmune diseases. The pathogenesis of cGVHD has not been fully elucidated [1]; however 266 
recent insights suggest that several players and different pathways are involved, including 267 
imbalance of T and B cells, and exaggerated collagen production; these phenomena are associated 268 
with typical alterations of the cytokine network, such as increased levels of transforming growth 269 
factor beta (TGFβ) and inflammatory cytokines. Similarly to what observed in systemic 270 
autoimmune diseases, a variety of autoantibodies have been reported in patients affected by 271 
cGVHD [2,3 and many of them develop multi-organ disease with fibrotic features, resembling 272 
systemic scleroderma (SSc); typical biological data are characterized by increased production of 273 
pro-fibrotic inflammatory cytokines such as platelet-derived growth factor (PDGF) and TGFβ 4,5]. 274 
Perturbation of regulatory T cell (Treg) homeostasis has also been reported as a contributing 275 
factor to both acute and cGVHD 6,7]. Moreover, B lymphocytes have recently been recognized as 276 
important players in the pathogenesis of cGVHD [8,9]; indeed, relevant clinical response rates 277 
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have been reported following Rituximab-induced B cell depletion [10]. In general, mild cGVHD only 278 
requires topic treatment and ancillary therapeutic measures; on the other hands, both moderate 279 
and severe cGVHD, defined according to the National Institute of Health consensus criteria, 280 
require systemic treatment [11]. The standard first-line systemic treatment of cGVHD consists of 281 
steroids with or without calcineurin inhibitors, yielding a response rate of 50-60%, [12-15]; 282 
however, the optimal treatment for steroid refractory cGVHD (sr-cGVHD) has still to be defined 283 
[16] and long-term steroid administration in steroid-dependent patients is associated with severe 284 
chronic toxicity. Imatinib, a first-generation Tyrosine Kinase Inhibitor (TKI) is currently used for 285 
treatment of Philadelphia-positive chronic myelogenous leukemia (CML) and acute lymphoblastic 286 
leukemia (ALL). This drug strongly inhibits both PDGF and TGFβ pathways in vitro; moreover, 287 
increasing concentrations of Imatinib prevent up-regulation of the major extracellular matrix 288 
(ECM) proteins COL1A1, COL1A2, and fibronectin 1 in PDGFβ and TGFβ-stimulated dermal 289 
fibroblasts. [17] Three prospective clinical trials suggest the potential usefulness of Imatinib in 290 
patients with sr-cGVHD [18-20]. In addition, preliminary data suggest that second-generation TKIs 291 
Nilotinib and Dasatinib could also be effective and well tolerated in patients with sr-cGVHD [21-292 
22]. In the few years, a pleiotropic anti-fibrotic and immune-modulating activity of these drugs has 293 
been reported [23-25]; these drugs interfere with tyrosine kinase-mediated intracellular pathways 294 
and inhibit TCR-mediated signal transduction, cellular proliferation, cytokine production, and T-cell 295 
responses [26]. Moreover some in vitro data suggest that Treg function can be hampered by 296 
therapeutic concentrations of Imatinib in CML patients [27]. Nevertheless, the interactions 297 
between TKIs and the different immune subpopulations have not been fully elucidated. To better 298 
define the potential role of TKIs as therapeutic agents in cGVHD, we investigated the in vitro effect 299 
of four different drugs (i.e Nilotinib, Dasatinib, Imatinib, Ponatinib) on T, B and NK lymphocyte 300 
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subpopulations; data obtained in vitro were subsequently correlated with data obtained from a 301 
cohort of patients receiving Nilotinib for sr-cGVHD. 302 
 303 
Materials and Methods 304 
Samples for in vitro experiments 305 
Peripheral blood samples were obtained after informed consent from residual unused blood 306 
collected from twenty healthy donors. Peripheral blood mononuclear cells (PBMC) were purified 307 
by density gradient centrifugation using Ficoll-Biocoll separation solution (MP Biomediacals, Santa 308 
Ana, California). Lymphocyte subpopulation frequencies were assessed by flow cytometry 309 
following culture, as described below. 310 
 311 
Samples for in vivo experiments 312 
PBMC and plasma samples were collected from patients participating to the Prospective, phase 313 
I/II, multicenter study to determine safety and efficacy of Nilotinib in a population with steroid-314 
refractory/or steroid-dependent cGVHD (EUDRACT: 2010-023068-41). The study was designed to 315 
assess efficacy, safety and tolerability of four different doses of Nilotinib (200, 300, 400 and 600 316 
mg/day) in patients affected by steroid refractory or steroid-dependent cGVHD. Samples were 317 
collected at baseline, after 90 and after 180 days of treatment; PBMC and plasma were 318 
subsequently frozen and stored at -80 °C; both lymphocyte subpopulation frequencies and 319 
cytokine production were assessed immediately after thawing (see below). 320 
 321 
Cell isolation and cultures 322 
CD3-positive T cells were purified from peripheral blood through positive selection by immune-323 
magnetic cell separation with MACS CD3 microbeads (Miltenyi Biotec, Cologne, Germany), 324 
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according to the manufacturer’s instruction; purity level obtained by the procedure was ≥90%, as 325 
assessed by flow cytometry (see below). Cells were placed in wells at the concentration 1x106 326 
cell/well and cultured for 96 hours in RPMI 1640 (EuroClone, Milan, Italy) supplemented with heat-327 
inactivated 10% fetal bovine serum (EuroClone), 2 mM L-glutamine and 100 units/ml penicillin- 328 
streptomycin (EuroClone). 329 
 330 
Incubation with tyrosine kinase inhibitors 331 
PBMC from healthy donors were cultured as previously described both in absence and in presence 332 
of increasing concentrations of tyrosine kinase inhibitors (TKIs) Nilotinib, Imatinib, Dasatinib and 333 
Ponatinib. TKIs for in vitro experiments were provided by Santa Cruz Biotechnology and stored in 334 
aliquots at -20°C as 10 mM stock solution in DMSO, protected from light until use. For culture 335 
purpose, stock solution was diluted by RPMI 1640 and added to T cell cultures at serial 336 
concentrations on the first day of culture. Final concentrations were the following: 1 µM, 10 µM, 337 
50 µM for Imatinib; 0,5 µM, 1 µM, 2 µM, 10 µM for Nilotinib; 50 nM, 100 nM, 200 nM for 338 
Dasatinib; 10 nM, 50 nM, 100 nM for Ponatinib. 339 
 340 
Flow cytometry 341 
Six-colour flow cytometry analysis was performed by FacsCanto II (Becton-Dickinson, Franklin 342 
lakes, New Jersey) after labelling cultured or patients-derived PBMC with the following conjugated 343 
monoclonal antibodies (Becton-Dickinson ): CD4*fluorescein isothiocyanate (FITC), CD16-344 
CD56*phycoerythrin (PE), CD3* phycoerythrin-Cyanine 7 (PE-Cy7), CD25* Allophycocyanin (APC) 345 
CD19* Allophycocyanin-Cyanine 7 (APC-Cy7), CD45RA* phycoerythrin (PE), transcription factor 346 
forkhead box P3 (FoxP3)* Peridinin Chlorophyll Protein-Cyanine 5.5, (PerCP-Cy5.5), 347 
CD127*phycoerythrin (PE), CD3* Allophycocyanin-Cyanine 7 (APC-Cy7), 7-Aminoactinomycin D 348 
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(7AAD). CD8 T cells were identified as CD3-positive and CD4-negative lymphocytes: to minimize 349 
possible overestimation, due to the presence of CD4- and CD8-double negative T cells, CD3-350 
positive cells with very high mean fluorescence intensity (mainly represented by the double 351 
negative T cells) were gated out if present. For extracellular staining, cells were incubated for 30 352 
min at room temperature with optimal dilution of each antibody, according to the manufacturer 353 
instructions. For intracellular staining, cells were fixed with Reagent A following surface labelling, 354 
then permeabilized with Reagent B (Becton-Dickinson) before intracellular staining. A minimum of 355 
50.000 cells per tube were acquired; frequencies of the different subpopulations were 356 
subsequently calculated by FacsDiva software (Becton-Dickinson). To analyze the effects of TKIs on 357 
regulatory T cells, CD3-positive and CD8-negative lymphocytes (CD4-positive T cells) were gated, 358 
and regulatory T cells were subsequently identified as CD25-positive, FOXP3-positive and CD127 359 
low or negative cells. 360 
 361 
Cytokine output in vitro and in vivo 362 
Purified cells were cultured as previously described; after 96 hours incubation with TKIs, 363 
supernatants were collected and cytokine concentrations were determined by Bio-Plex (Bio-Rad, 364 
Hercules, California), according to the instruction of Bio-Plex Pro Human Cytokine 17-plex Assay 365 
(Bio-Rad). Plasma samples from Nilotinib-treated patients and purified CD3-positive cells from 366 
healthy donors were also analyzed after thawing. Cytokines included in the panel were the 367 
following: IL2, IL4, IL10, IL17, IFNγ, TNFα. The Bio-Plex immunoassays are formatted on magnetic 368 
beads, based on a principle like a sandwich ELISA. Coupled beads react with the sample containing 369 
the biomarker of interest. After a series of washes to remove unbound protein, a biotinylated 370 
detection antibody is added to create a sandwich complex. The final detection complex is formed 371 
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with the addition of streptavidin-phycoerythrin conjugate. This kind of assay is able to quantify 372 
multiple protein biomarkers in a single well of a 96-well plate. 373 
 374 
Statistical analysis 375 
Data were compared as mean ± standard deviation (SD). Differences were assessed by two-tailed 376 
Student's t-test or Pearson’s test and were considered statistically significant when p<0.05.  377 
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Results 378 
In vitro effects of tyrosine kinase inhibitors on lymphocyte subpopulations 379 
PBMC from healthy donors were cultured in presence of increasing concentrations of different 380 
TKIs; lymphocytes were gated by forward scatter (FSC) and side scatter (SSC) profile. 381 
Subpopulations were identified on gated lymphocytes as CD3- and CD4- double positive (T helper 382 
cells), CD3-positive and CD4-negative (T cytotoxic cells); CD19-positive (B lymphocytes); CD16- and 383 
CD56-double positive (Natural Killer cells, NK). As shown in table 1, exposure to increasing 384 
concentration of Imatinib (1 to 50 µM), Nilotinib (0.5 to 10 µM), Dasatinib (up to 100 nM) and 385 
Ponatinib (up to 50 nM) did not significantly affect the proportions of T cells. However, very high 386 
concentration of Dasatinib (200 nM) and Ponatinib (100nM) induced a sharp and profound 387 
decrease of total T lymphocytes (from 75.9% to 0% for both drugs, p<0.02), associated with a 388 
proportional increase of T cell death rate (from 0.1% to 100% for both drugs, p<0.02). This effect 389 
was observed both for T helper CD4 and for cytotoxic CD8-positive T cell subsets (supplementary 390 
figure S1 and S2). Both B an NK cells showed a progressive and significant reduction after exposure 391 
to increasing concentrations of either Imatinib, Dasatinib and Ponatinib. As shown in table 1, B 392 
cells decreased from 9.1% to 7.4% (p= NS), 5.7% (p<0.05) and 4.6% (p<0.02) following incubation 393 
with 1M, 10M and 50M of Imatinib, respectively; to 3.4% (p<0.02), 3.5% (p<0.02) and 0% 394 
(p<0.02) following 50nM, 100 nM and 200nM of Dasatinib respectively; to 3.5% (p<0.02), 1.7% 395 
(p<0.02) and 0% (p<0.02) following 10nM, 50nM and 100nM of Ponatinib, respectively. Similarly, 396 
NK cell frequencies were reduced from 7.2% to 6.2% (p=NS), 6,1% (p<0.05) and 2.5% (p<0.05) by 397 
Imatinib; to 3.2% (p<0.02), 2.4% (p<0.02) and 0% (p<0.02) by Dasatinib; to 5% (p<0.02), 1.9% 398 
(p<0.02) and 0% (p<0.02) by Ponatinib. All these changes were paralleled by proportional 399 
increases in B lymphocytes and NK cell death rates (table 1). On the contrary, increasing in vitro 400 
concentrations of Nilotinib did not exert any significant impact on these two subpopulations (table 401 
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1); compared to baseline, no significant changes were observed in the proportion of both B 402 
lymphocytes (9.1 vs 8.6% p=NS) and NK cells (7.2 vs 5.5% p=NS), even at the highest drug 403 
concentration (10 M). Taken together, these data suggest that: 1) compared to B lymphocytes 404 
and NK cells, T lymphocytes are more resistant to the toxic effects of all the TKIs tested; 2) 405 
Nilotinib appears to be less toxic than the other TKIs tested, being the only drug not exerting any 406 
significant impact on B lymphocytes and NK subset. 407 
 408 
 409 
In vitro effects of tyrosine kinase inhibitors on regulatory T cells 410 
As shown in figure 1 (panels A, C-D), in vitro exposure to Imatinib, Dasatinib and Ponatinib induced 411 
a sharp and progressive decrease of regulatory T cells proportion, statistically significant starting 412 
from the lowest drug concentration in culture (p<0.02); a decrease of regulatory T cells was also 413 
induced by Nilotinib, but only at concentrations 2 μM or higher (Figure 1, panel B). The 414 
contribution of cell death to the decrease of regulatory T cells observed following exposure to TKIs 415 
was also investigated (Figure 1, panels E-H). A progressive increase of apoptotic regulatory T cells 416 
was observed after exposure to increasing concentrations of Dasatinib and Ponatinib (Figure 1, 417 
panels G-H). Regulatory T cell viability was also impaired by increasing concentration of Imatinib 418 
(Figure 1, panel E), albeit to a lesser extent; again, incubation with Nilotinib was followed by an 419 
increase of regulatory T cell apoptosis that was mild and only observed at the highest 420 
concentrations of the drug (Figure 1, panel F). Of note, the reduction of the proportion of 421 
regulatory T cells did not involve naïve subset (identified as CD45RA-positive Treg); in fact, 422 
exposure to increasing concentrations of TKIs (with the only exception of Dasatinib) was followed 423 
by accumulation of these cells (Figure 2, panels A-D). These in vitro data suggest that: 1) overall, 424 
exposure to TKIs induce a profound decline of total regulatory T cells; 2) Nilotinib constitutes an 425 
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exception, unlike the other TKI, this drug does not impair regulatory T cells frequencies at 426 
therapeutic concentrations; 3) the decline observed in total regulatory T cells does not involve 427 
naïve cells, whose frequency increase following exposure to all the TKIs tested. 428 
 429 
In vitro effects of tyrosine kinase inhibitors on T cell cytokine production 430 
To investigate how TKIs can influence cytokine production by T cells, sorted CD3-positive cells 431 
were incubated with increasing concentrations of Imatinib, Nilotinib, Dasatinib, and Ponatinib; 432 
after 96-hour culture, supernatants were collected and cytokine levels were measured (Figure 3). 433 
Increasing concentrations of all the tested TKIs induced a consistent reduction of IL17 levels in 434 
culture supernatants compared to baseline (31.5±18.3 pg/ml; figure 3, panel C). However, this 435 
effect was remarkably pronounced with therapeutic concentrations of Imatinib (1 and 10 µM; 436 
16.4±11.1 and 7.9±3.1 pg/ml, p<0.02) and Nilotinib (2 µM; 3.9±2.3 pg/ml, p<0.05), whereas it 437 
appeared less pronounced with therapeutic concentration of Dasatinib (50-100 nM, p=NS) and 438 
Ponatinib (10-50 nM, p=NS). TKIs induced a profound reduction of the concentrations of pro-439 
inflammatory cytokines IL2, IFNγ and TNFα in supernatants (Figure 3, panels A, E-F), starting from 440 
the lowest drug concentrations; IL10 production was also strongly impaired by all the TKIs studied 441 
(Figure 3 panel D). On the contrary, the production of IL4 (Figure 3, panel B) was barely affected by 442 
TKIs (except Ponatinib). Taken together these data: 1) show that all the tested TKIs exert common 443 
anti-inflammatory effects; 2) suggest that, at therapeutic concentrations, some TKIs (i.e. Imatinib 444 
and Nilotinib) down-regulate pro-inflammatory Th17 cells activity more efficiently than others (i.e. 445 
Dasatinib and Ponatinib). 446 
 447 
In vivo effects of Nilotinib on T cell subpopulations of patient with cGVHD 448 
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To assess whether the in vitro effects of TKIs on lymphocyte phenotype and function can also be 449 
observed in an in vivo setting, we evaluated 15 patients affected by steroid-dependent or steroid-450 
refractory cGVHD that underwent treatment with Nilotinib in the setting of a phase 1-2 451 
prospective multicenter study (see Material and Methods). Eight out of the 15 patients were still 452 
taking steroids and seven were treated with cyclosporine (2 mg/kg) when Nilotinib was started. 453 
We have previously shown [28] that mean plasma concentrations of Nilotinib was 817 ng/ml 454 
(±450) in all patients (corresponding to 1.6 µM ±0.9). Mean plasma trough level at the steady-state 455 
was 1.4 µM at 200 mg/die (range 0.4-2.1), 2.0 µM at 300 mg/die (range 0.6-5.0), 1.2 µM at 400 456 
mg/die (range 0.1-2.1) and 4.7 µM for 600 mg/die (1 patient only). Figure 4 shows the overall 457 
frequencies of T, B and NK lymphocyte subsets in cGVHD patients receiving Nilotinib; no significant 458 
changes were observed in T and B lymphocyte proportions, irrespective of treatment schedule 459 
(not shown). NK cells proportions were also substantially preserved (Figure 4); in fact, a significant 460 
decrease of this subset was only observed when the highest dose of Nilotinib was given for 180 461 
consecutive days (not shown). Collectively, these finding confirm the data observed in vitro and 462 
suggest that in patients with cGVHD the administration of Nilotinib does not induce relevant 463 
changes of the relative proportions of the main lymphocyte subpopulations, at least at the lowest 464 
doses. 465 
 466 
In vivo effects of Nilotinib on T cell cytokine production 467 
To investigate the impact of Nilotinib on cytokine network in vivo, we measured the cytokine 468 
concentrations in thawed plasma samples collected from Nilotinib-treated patients, as described 469 
in “Materials and Methods” section. As shown in figure 5, the administration of Nilotinib was 470 
associated with strong decrease in the production of pro-inflammatory cytokines, IL2 and IFNγ. 471 
IL10, TNFα levels and IL17 were also reduced in patients’ plasma samples following therapy, 472 
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although the latter two were mainly affected by longer duration of treatment (180 days) and by 473 
administration of higher drug doses (400 mg/daily). On the contrary, Nilotinib did not induce 474 
relevant changes in the production of IL4. These data confirm those generated in vitro, further 475 
suggesting that treatment with Nilotinib is associated with a consistent reduction of pro-476 
inflammatory cytokines production, including IL17.  477 
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Discussion 478 
To date, no standard treatment is available for SR-cGVHD [13]. Donor derived CD4 and CD8-479 
positive T lymphocytes have been considered important effectors mediating cGVHD pathogenesis, 480 
although recent studies suggest that B cells might also play a role [8,29-30]. In vitro data suggest 481 
that TKIs strongly modulate both T- and B-cell mediated immune responses [25,31] while 482 
preliminary clinical data suggest a promising efficacy of both Imatinib and Nilotinib on SR-cGVHD 483 
[32]. In the present study, we first investigated the in vitro effects of four different TKIs (Nilotinib, 484 
Dasatinib, Imatinib, Ponatinib) on lymphocyte numbers and function. We observed heterogeneity 485 
in lymphocyte subsets susceptibility, according to the kind and concentration of TKI evaluated. 486 
Overall, T cell frequencies were not consistently affected by therapeutic doses of TKIs, whereas 487 
the proportions of B and NK cell showed a robust and linear decline, following exposure to 488 
increasing amounts of all the TKIs, except Nilotinib.  489 
 490 
Clinical studies have linked NK cells to outcome following stem cell transplant (SCT); indeed, 491 
patients receiving SCT bearing high numbers of NK cells are less likely to develop acute and cGVHD 492 
[33,34]. These findings are consistent with mice models showing that donor NK cells can eradicate 493 
recipient antigen presenting cells (APCs) thereby preventing GVHD [35]. Among the different TKIs 494 
tested in the present study, only Nilotinib could preserve NK cells (p<0.01), thus suggesting that 495 
the immune modulatory effect of this drug may be more balanced toward an efficient control of 496 
GVHD compared to other TKIs. However, Nilotinib did not exert any significant effect on B cells, 497 
recognized as important players in the pathogenesis of cGVHD. [8]. 498 
 499 
In preclinical murine transplant models Tregs are able to prevent alloreactive T cell responses and 500 
experimentally induced GVHD, and recent studies suggest a role for Tregs in the protection from 501 
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both acute and cGVHD. [36-38]. In our model, whereas in vitro exposure to increasing doses of 502 
Imatinib, Dasatinib and Ponatinib induced a progressive and significant decrease (p<0.01) of total 503 
Tregs, Nilotinib reduced the frequency of this subpopulation only at concentrations exceeding 2 504 
μM (p<0.01), i.e. above those usually achieved in vivo. This finding is in line with previously 505 
published data, pointing out a possible relationship between Tregs kinetics and Nilotinib dosage. 506 
[39]. It has been recently showed that high frequencies of naïve regulatory T cells are associated 507 
with lower risk of acute GVHD following haploidentical or sibling identical SCT [40], thus suggesting 508 
that different Treg subsets can exert a different impact on the outcome of SCT. The protective role 509 
of naïve T regulatory cell subset has also been showed in other clinical condition, such as 510 
pregnancy-associated pre-eclampsia, preterm delivery and gestational diabetes mellitus [41-42]. 511 
Of note, in the present study the frequency of naïve T regulatory cells increased following 512 
exposure to all the TKIs tested, suggesting that despite inducing the overall reduction of the total T 513 
regulatory cell pool, these drugs may indeed lead to the accumulation of T regulatory subsets 514 
provided with high immune modulating activity against GVHD. 515 
 516 
Cytokine production is a key process by which activated T cells exert their immune responses and 517 
is involved in development and evolution of conditions characterized by immune hyper-activation, 518 
such as GVHD and transplant rejection. Of note, in the present study pro-inflammatory cytokine 519 
concentrations (including IL17) decreased significantly in culture supernatants following exposure 520 
to all the TKIs tested.  521 
Overall, the results from our in vitro experiments suggest a peculiar and balanced activity of 522 
Nilotinib on lymphocyte’s immune modulation: like other TKIs, this drug interacts with innate and 523 
adaptive immune response, showing anti-inflammatory properties; however, unlike other TKIs, 524 
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Nilotinib is able to better preserve cell subsets that have been shown to prevent the development 525 
of immune responses associated with GVHD, such as Treg and NK cells.  526 
 527 
Based on these in vitro data, we further address the effect of Nilotinib on lymphocyte 528 
subpopulations and function in an in vivo setting, by analyzing blood samples from 15 patients 529 
affected by steroid-refractory cGVHD, after 90 or 180 days of therapy. To our knowledge, this is 530 
the first study addressing simultaneously both in vitro and in vivo effects of Nilotinib by the same 531 
experimental approach. Overall, the in vivo data confirm those obtained in vitro, showing that 532 
Nilotinib: 1) induces a consistent reduction of pro-inflammatory cytokines production, particularly 533 
IL2 and IFNγ: 2) substantially preserves lymphocyte subpopulations frequencies.  534 
In addition, Nilotinib did not affect significantly Tregs frequency, although the phenotypic 535 
definition of this subpopulation in vivo did not include FoxP3 and CD127 (which were instead 536 
included in the phenotypic evaluation of this same subset in vitro), due to limited amount of 537 
samples available and to technical issues related to intracellular staining of thawed cells; adequate 538 
studies are needed to better define the kinetics of T regulatory cells following exposure to TKIs in 539 
vivo. The experiments were conducted on thawed samples, therefore the impact of Nilotinib on 540 
absolute numbers deserve further investigation. Compared to the in vitro findings, the in vivo 541 
administration of Nilotinib induced a slight, non-significant decrease of IL17 in plasma sample. The 542 
reasons of this discrepancy are unclear; however, we cannot exclude that this discrepancy could 543 
be related to differences between the kind of samples used for in vitro and in vivo studies; the 544 
former were in fact obtained from healthy donors, whereas the latter were collected from 545 
individuals exposed to different immunosuppressant drugs including steroids, and possibly 546 
affected by co-morbidities requiring additional therapy (i.e. anti-inflammatory drugs, 547 
antimicrobials, etcetera). Collectively, our data support the use of TKIs, Nilotinib in particular, in 548 
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patients developing cGVHD following SCT, and emphasize the broad and potent anti-inflammatory 549 
effect of Nilotinib and other TKIs, supported by the robust decline of all the pro-inflammatory 550 
cytokines included in the analysis. Further studies are necessary to better clarify the clinical impact 551 
and safety of different TKIs in this clinical setting; in particular, additional investigation by 552 
adequately powered clinical trials is required to understand whether the experimental data 553 
provided by this study will translate into clinical benefits for patient affected by steroid refractory 554 
cGVHD. As cGVHD can involve many different organs such as skin, liver and lungs, further studies 555 
are also needed to address the therapeutic effectiveness of Nilotinib (and other TKIs) on different 556 
body districts. Moreover, the negative (although not significant at least for Nilotinib) impact of 557 
TKIs on the total T regulatory cell pool frequencies could suggest a possible association of TKIs 558 
with other treatments aimed to increase the Treg populations (e.g. IL2 low dose or extracorporeal 559 
photopheresis) [43-44] in order to increase the response rate in these patients. Finally, the role of 560 
different T regulatory subset in controlling cGVHD following SCT should be further addressed, as 561 
the accumulation of naïve Tregs may impact more favorably than other subsets on the prevention 562 
of cGVHD development.  563 
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Figure 1 – Changes in T regulatory cells frequencies and death rate proportions following 691 
exposure to TKIs in vitro 692 
Lymphocytes were gated by forward scatter (FSC) and side scatter (SSC) profile. T regulatory 693 
cells were identified by the co-expression of CD3, CD4, CD25 surface markers and FoxP3 694 
intracellular marker (line plots, panels A-D); dying cells were identified by the expression of the 695 
marker 7AAD on the surface of CD3, CD4 and CD25-positive cells (bar plots, panels E-H). 696 
Results are expressed as percentages on total CD25-positive cells. Means and standard 697 
deviations are reported; *p<0.05; **p<0.02. 698 
 699 
Figure 2 – Naive T regulatory cells frequencies following exposure to TKIs in vitro 700 
Lymphocytes were gated by forward scatter (FSC) and side scatter (SSC) profile. Naïve T 701 
regulatory cells were identified by the expression of the marker CD45RA on the surface of CD3, 702 
CD4, CD25 and FoxP3-positive cells (line plots, panels A-D). Results are expressed as 703 
percentages on total T regulatory cells. Means and standard deviations are reported; *p<0.05; 704 
**p<0.02. 705 
 706 
Figure 3 – T cell production of pro-inflammatory and immuno-modulatory cytokines 707 
following exposure to TKIs in vitro 708 
T cells were purified from PBMCs through positive selection by magnetic cell separation CD3 709 
microbeads and cultured. Cytokine production was measured on cell culture supernatants; 710 
baseline values (pg/ml) are compared to results obtained following exposure of cells to 711 
increasing concentrations of each TKI. Means and standard deviations are reported; *p<0.05; 712 
**p<0.02.  713 
Figure 4 – Lymphocyte subpopulations changes following exposure to Nilotinib in vivo 714 
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PBMCs obtained from SR-cGVHD affected patients treated with Nilotinib at different dose 715 
schedule were thawed, labeled with monoclonal antibodies and examined by flow cytometry. 716 
Frequencies of T, B and NK subset are shown. Average values and standard deviation at 717 
baseline (white bars) and following 90 days (light gray bars) and 180 days (dark grey bars) of 718 
therapy are reported. Values are expressed as percentage of total lymphocytes; changes 719 
induced by different Nilotinib dose schedules are represented together.  720 
 721 
Figure 5– Modification of cytokine production following exposure to Nilotinib in vivo 722 
Cytokine concentrations were determined on plasma samples from Nilotinib-treated patients 723 
after thawing. Average values and standard deviation at baseline (white bars) and following 90 724 
days (light gray bars) and 180 days (dark grey bars) of therapy are reported. Changes induced 725 
by different Nilotinib dose schedules are represented together. *p<0.05; **p<0.02. 726 
 727 
Supplementary figure S1 – T helper cells frequencies and death rate proportions following 728 
exposure to TKIs in vitro 729 
Lymphocytes were gated by forward scatter (FSC) and side scatter (SSC) profile. Changes of 730 
CD4-positive T cell frequencies (line plots, panels A-D) and death rates (bar plots, panels E-H) 731 
following exposure to different TKIs are represented. Means and standard deviations are 732 
reported; *p<0.05; **p<0.02. 733 
 734 
Supplementary figure S2 – T cytotoxic cells frequencies and death rate proportions following 735 
exposure to TKIs in vitro 736 
Lymphocytes were gated by forward scatter (FSC) and side scatter (SSC) profile. T cytotoxic 737 
cells were identified as CD3-positive and CD4-negative lymphocytes. Changes of cell 738 
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frequencies (line plots, panels A-D) and death rates (bar plots, panels E-H) following exposure 739 
to different TKIs are represented. Means and standard deviations are reported; *p<0.05; 740 
**p<0.02. 741 
 742 
 743 
 744 
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Table 1 – Lymphocyte subpopulations changes following exposure to increasing TKIs concentrations 745 
 TKI concentration  T lymphocytes (%)  B lymphocytes (%)  NK cells (%)  T lymphocytes 
death rate (%)  
B lymphocytes 
death rate (%)  
NK cells 
death rate (%)  
 baseline  75.9 ± 3.8 3 9.1 ± 2.02 7.2 ± 0.65 0.1 ± 0.05 0.0 0.7 ± 0.25 
IMATINIB  
1 μM  81.1 ± 4.17 7.4 ± 3.01 6.2 ± 1.47 0.3 ± 0.08** 0.02 ± 0.04 0.9 ± 0.28 
10 μM  84.5 ± 1.79 5.7 ± 2.18* 6.1 ± 1.24* 0.4 ± 0.04** 0.04 ± 0.05 1.3 ± 0.37* 
50 μM  78.2 ± 6.38 4.6 ± 1.30** 2.5 ± 0.87* 1.9 ± 0.58 ** 0.7 ± 0.11* 3.5 ± 1.61** 
NILOTINIB  
0,5 µM  76.9 ± 2.37 8.7 ± 2.79 6.6 ± 0.97 0.2 ± 0.15 0.04 ± 0.09 1.0 ± 0.30 
1 µM  73.5 ± 4.02 8.7 ± 4.81 6.2 ± 1.23 0.2 ± 0.10 0.3 ± 0.29 1.2 ± 0.32 
2 µM  79.9 ± 3.79 8.5 ± 2.58 5.8 ± 1.79 0.3 ± 0.11* 0.1 ± 0.22 1.0 ± 0.43 
10 µM  77.5 ± 3.48 8.6 ± 2.53 5.5 ± 1.54 0.4 ± 0.16* 0.1 ± 0.22 1.0 ± 0.32 
DASATINIB  
50 nM  76.8 ± 2.81 3.4 ± 0.77** 3.2 ± 0.70** 1.3 ± 0.71* 0.2 ± 0.17* 1.5 ± 0.38* 
100 nM  71.8 ± 3.01 3.5 ± 1.06** 2.4 ± 0.83** 2.8 ± 0.87** 0.9 ± 0.36** 3.1 ± 0.50** 
200 nM  0.0**  0.0** 0.0** 100 ± 0.00** 100 ± 0.00** 100 ± 0.00** 
PONATINIB  
10 nM  81.7 ± 5.41 3.5 ± 0.92** 5.0 ± 0.39** 0.7 ± 0.13** 0.1 ± 0.00* 2.2 ± 0.53** 
50 nM  88.2 ± 4.66 1.7 ± 0.65** 1.9 ± 0.76** 1.5 ± 0.22** 2.7 ± 2.05* 22.5 ± 3.47** 
100 nM  0.0** 0.0** 0.0** 100 ± 0.00** 100 ± 0.00** 100 ± 0.00** 
T, B and NK subpopulation frequencies and death rates are reported; baseline values are compared to results obtained following exposure of 746 
cultured cells to increasing concentrations of each TKI. Lymphocytes were gated by forward scatter (FSC) and side scatter (SSC) profile. T 747 
lymphocytes were identified as CD3-positive cells; B Lymphocytes were identified as CD3-negative CD19-positive cells; NK cells were identified 748 
as CD3-negative CD16 and CD56-double positive cells.  Means and standard deviations are reported; *p<0.05; **p<0.02. 749 
 750 
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